Abstract 606P
Background
Cutaneous melanoma is considered a rare but lethal cancer among Asians. Prognosis is generally worse with high rates of recurrences and mortality. Clinical presentations show striking differences with cutaneous melanoma among Caucasian. Acral lentiginous and nodular melanoma are the most common subtypes among Asian. Patterns of mutations and molecular alterations and the association with prognosis are not yet known among melanoma patients in Indonesia. This study aims to analyze association between BRAF dan NRAS mutations with overall survival of melanoma patients in Indonesia.
Methods
DNA from formalin-fixed paraffin embedded tissues from melanoma patients were extracted. PCR and pyrosequencing were performed to detect mutations in the BRAF dan NRAS genes.
Results
Of 51 melanoma patients, 44 patients (86.3%) were diagnosed with Breslow thickness more than 4 mm (T4). In the primary cutaneous melanoma lesions, 33 (67%) patients had ulceration, 47 patients (92.2%) had diameter more than 6 mm, and 30 patient (58.2%) had positive regional lymph nodes. In this study, BRAF mutations were found in 26 patients (56%) and NRAS mutations were found in 5 patients (9.8%). BRAF mutations were found in older age than 65 years although the difference was not significant (OR 2.205, 95%CI: 0.558-8.717, P=0.259). BRAF mutations were associated with significantly lower overall survivals compared to wild-type (median survivals were 18 vs 34 months, P=0.042). Although patients with NRAS mutations had shorter survival, the difference was not statistically significant (P=0.120). Patients with BRAF or NRAS were associated with significant lower overall survivals compared to those with wild-type (Median survivals were 19 vs 35 months, P=0.044).
Conclusions
BRAF and / or NRAS mutations were associated with shorter survival among cutaneous melanomas in Indonesia with predominant subtypes of acral lentiginous and nodular melanomas. Larger study from Asian population is required to extend our finding to establish a prognostic marker as well as a potential targeted treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gadjah Mada University.
Funding
Gadjah Mada University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract